HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antimicrobial waterless hand sanitizers food handlers' target use in HCCM questioned.

This article was originally published in The Rose Sheet

Executive Summary

ANTIMICROBIAL HAND SANITIZER POSITION IN HCCM CHALLENGED by FDA Anti-infective Drugs Division microbiologist David Bostwick during the first in a series of technical "feedback meetings" on antimicrobial food handler products held by the Center for Drug Evaluation & Research OTC Drugs Division in Rockville, Md. During the general session of the July 21 meeting, Bostwick questioned the inclusion of hand sanitizers in the proposed Healthcare Continuum Model given the products' broad target use, which ranges from home food preparation to use by slaughterhouse workers. He explained that other food handler antimicrobials provide better protection against organisms, and asked, "what is the rationale" for the inclusion of waterless hand sanitizers if the HCCM "already covers [them] in...other types of products."
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS005638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel